18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants
Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection
About this trial
This is an interventional diagnostic trial for Pancreatitis, Graft
Eligibility Criteria
Inclusion Criteria:
- 18 or over in age
- Have any type of pancreatic transplant
- Able to consent for 18F-Fluciclovine PET/CT scan
- For archived 18F-Fluciclovine PET/CT scan reviews, only scans of non-diabetic patients will be included.
Exclusion Criteria:
- Patient with known prostate cancer
Sites / Locations
- University of Utah Hospital
Arms of the Study
Arm 1
Experimental
18F fluciclovine Administration
Initial normal standardized uptake values (SUV) of the pancreas, liver, and blood pool will be obtained from 50archived previous 18F-Fluciclovine studies, as there are no normal ranges in the literature. This will be done by retrospective medical record review after a waiver of consent/authorization is obtained from the local IRB. Informed consent will be obtained from 10 patients with pancreatic allografts, and each will undergo an 18F-Fluciclovine study. These patients will not be suspected of having current rejection or allograft dysfunction. Timing of 18F-Fluciclovine PET/CT scans will be planned to coincide with standard-of-care imaging studies and laboratory tests. The 18F-Fluciclovine study will be compared with the patients' standard-standard-of-care US and/or CT with the assessment of ease of visualization of the pancreatic allograft.